XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Schedule of Revenues from Major Customers (Detail) - Product Concentration Risk [Member] - Revenue Benchmark [Member]
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Largest Customer | HEPLISAV-B    
Concentration Risk [Line Items]    
Percentage of product revenue 27.00% 25.00%
Second Largest Customer | HEPLISAV-B    
Concentration Risk [Line Items]    
Percentage of product revenue 22.00% 20.00%
Third Largest Customer | HEPLISAV-B    
Concentration Risk [Line Items]    
Percentage of product revenue 17.00% 16.00%
Largest Collaboration Partner | CpG 1018 adjuvant    
Concentration Risk [Line Items]    
Percentage of product revenue 0.00% 74.00%
Second Largest Collaboration Partner | CpG 1018 adjuvant    
Concentration Risk [Line Items]    
Percentage of product revenue 0.00% 24.00%
Third largest collaboration partner | CpG 1018 adjuvant    
Concentration Risk [Line Items]    
Percentage of product revenue 0.00% 2.00%